Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Chemotherapy
This collaborative effort demonstrated the feasibility of aligning disparate data sources to evaluate rw-response end points using clinician-documented responses in patients with mNSCLC. Heterogeneity exists in the availability of data components to assess response and related rw-end points, and further work is needed to inform drug effectiveness evaluation within RWD sources.
Authors
- Janet L. Espirito (ORCID: https://orcid.org/0009-0000-7741-3573)
- Elizabeth G. Bond (ORCID: https://orcid.org/0000-0002-1621-5503)
- Jeff Allen (ORCID: https://orcid.org/0000-0002-0586-3054)
- Andrea McCracken (ORCID: https://orcid.org/0000-0002-4500-7236)
- Elizabeth Garrett‐Mayer (ORCID: https://orcid.org/0000-0003-4709-0333)
- Connor Sweetnam (ORCID: https://orcid.org/0000-0002-4275-0569)
- Yanina Natanzon (ORCID: https://orcid.org/0000-0002-9302-0304)
- Mark Stewart (ORCID: https://orcid.org/0000-0002-4847-0736)
- Regina M. Schwind (ORCID: https://orcid.org/0000-0002-3374-3455)
- Danielle Potter (ORCID: https://orcid.org/0000-0002-0986-8717)
- Hillary S. Andrews (ORCID: https://orcid.org/0000-0002-0177-2024)
- Paul G. Kluetz (ORCID: https://orcid.org/0000-0002-9796-4791)
- Joseph Wagner (ORCID: https://orcid.org/0000-0002-1776-3819)
- Lawrence H. Schwartz
- Donna R. Rivera (ORCID: https://orcid.org/0000-0002-4565-4556)
- Amanda Bruno (ORCID: https://orcid.org/0009-0007-6721-2234)
- Pallavi S. Mishra‐Kalyani (ORCID: https://orcid.org/0000-0003-2309-0179)
- Lauren Damato
- Nicholas J. Robert (ORCID: https://orcid.org/0000-0002-8491-5392)
- Xinran Ma (ORCID: https://orcid.org/0000-0002-7138-2638)
- Laura L. Fernandes (ORCID: https://orcid.org/0000-0002-5986-3885)
- Amy Alabaster (ORCID: https://orcid.org/0000-0003-2860-1759)
- Brittany A. McKelvey (ORCID: https://orcid.org/0000-0001-9239-7153)
- Eric Hansen
- Thomas D. Brown (ORCID: https://orcid.org/0000-0002-2123-1014)
Institutions
- American Society of Clinical Oncology (US)
- United States Food and Drug Administration (US)
- Memorial Sloan Kettering Cancer Center (US)
- Syneos Health (United States) (US)
- IQVIA (United States) (US)
- Concert Pharmaceuticals (United States) (US)
- Tempus Labs (United States) (US)
- Flatiron Health (United States) (US)
- Research Network (United States) (US)
- Friends of Cancer Research (US)
Publication Details
- Journal
- JCO Clinical Cancer Informatics
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1200/cci.24.00091
- Citations
- 9
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.77
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Celgene
- Varian Medical Systems
- Regeneron Pharmaceuticals
- Moderna
- Flatiron Health